Acer Therapeutics Inc.

107 articles with Acer Therapeutics Inc.

• Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update

  3/27/2023

  Acer Therapeutics Inc. (Nasdaq: ACER) today reported financial results for Q4 and full year ended December 31, 2022, and provided an update on the Company’s recent corporate developments.

• Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes

  3/22/2023

  Acer Therapeutics Inc. (Nasdaq: ACER) today announced data was presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders (UCDs) at the 44th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD), March 18th-21st in Salt Lake City, Utah.

• Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

  3/22/2023

  Acer Therapeutics Inc. announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company’s common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

• Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women

  3/17/2023

  Acer Therapeutics Inc. (Nasdaq: ACER) today announced that topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant).

• Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update

  3/15/2023

  Acer Therapeutics Inc. (Nasdaq: ACER) today announced data will be presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders (UCDs) at the upcoming 44th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD), March 18th-21st in Salt Lake City, Utah.

• Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseTopline trial results expected mid-March 2023

  2/13/2023

  Acer Therapeutics Inc. (Nasdaq: ACER) today announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist, being investigated as a potential treatment option for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.

• Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones

  1/9/2023

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.

• Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

  1/5/2023

  Acer Therapeutics Inc. today announced the initiation of two Phase 2, single-arm investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of the prostate.

• Acer Therapeutics Compliant with All Nasdaq Listing Criteria

  12/29/2022

  Acer Therapeutics Inc. announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the $35 million market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing on The Nasdaq Capital Market.

• Acer Therapeutics Announces $1.5M Private Placement

  11/30/2022

  Acer Therapeutics Inc. announced that it has entered into definitive agreements with its CEO as well as its Chairman for a private placement of its securities for gross proceeds of $1.5 million.

• Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate Update

  11/14/2022

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2022 and provided an update on Acer’s recent corporate developments.

• Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)Notice of allowance of celiprolol method of treatment of vEDS patent application strengthens proprietary position in U.S. until 2038

  10/26/2022

  Acer Therapeutics Inc. (Nasdaq: ACER) today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Acer’s patent application No. 16/930,208, exclusively licensed from Assistance Publique—Hôpitaux de Paris, for claims related to certain methods of treating vascular Ehlers-Danlos syndrome (vEDS) with celiprolol.

• Acer Therapeutics Announces University of NC Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency and Severity of Post-Traumatic Stress Disorder

  10/6/2022

  Acer Therapeutics Inc. announced that the University of North Carolina Institute for Trauma Recovery has been awarded a $3 million grant from the Department of Defense to investigate the potential of ACER-801 to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder.

• Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress Disorder

  10/5/2022

  Acer Therapeutics Inc. today announced the expansion of ACER-801 (osanetant) into a new indication, for the reduction of the frequency and severity of acute stress disorder and post-traumatic stress disorder (PTSD).

• Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

  10/3/2022

  Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding SA today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Acer for US patent application No. 16/624,834 for claims related to a kit comprising a combination therapeutic product composed of sodium phenylbutyrate or glycerol phenylbutyrate and sodium benzoate.

• Acer Therapeutics to Participate in August and September 2022 Investor Conferences

  8/23/2022

  Acer Therapeutics Inc. (Nasdaq: ACER), today announced that Acer’s management team will virtually present at, and participate in, the upcoming Gilmartin Group Emerging Growth Company Showcase and H.C. Wainwright 24th Annual Global Investment Conference.

• Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update

  8/15/2022

  Acer Therapeutics Inc. (Nasdaq: ACER), today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

• Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

  8/12/2022

  RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), today announced that the European Commission has granted orphan medicinal product designation in the EU to ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD).

• Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023

  7/28/2022

  Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the U.S. Food and Drug Administration (FDA) has accepted for review Acer’s resubmitted New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).

• Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

  7/28/2022

  Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the efficacy and safety of ACER-001.